Up to $75,000,000 of Shares of Common Stock (par value $0.0013 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • October 12th, 2018 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
